From Registration to Publication by 
PLoS Medicine  |  www.plosmedicine.org 093
Open access, freely available online
Editorial
November 2004  |  Volume 1  |  Issue 2  |  e46
I
n a compelling essay in this issue 
of PLoS Medicine, Mike Clarke, the 
director of the United Kingdom 
Cochrane Centre, lays down a challenge 
to clinical researchers and journal 
editors [1]. He argues that researchers 
should do a study only if there is a 
systematic review that shows that the new 
study is needed. If no review exists, the 
researchers should do one themselves 
before embarking on their research. 
And journals, he argues, should publish 
a study only if an updated systematic 
review is incorporated into the study, 
or published alongside it or shortly 
thereafter. How should editors respond 
to his challenge?
First, we would argue that by the time 
a paper is sent to a journal, it is surely 
too late in the process to be insisting 
on systematic reviews. If a clinical trial 
report meets our criteria for originality, 
importance, and quality, it makes little 
sense for us to reject it just because 
the authors failed to systematically 
review the literature when designing 
their study. The time to mandate 
that researchers do a review is much 
earlier—when they apply for funding, 
register their trial, or seek ethics 
committee approval.
There is no doubt that the best 
research builds on previous knowledge. 
But unfortunately, the current medical 
publishing system hides much of this 
knowledge behind subscription or “pay 
per view” charges, which discriminates 
against researchers who do not work 
for well-funded institutions. A group of 
researchers in Indonesia, for example, 
recently told a depressingly familiar 
story of trying to search the medical 
literature in preparation for a research 
project [2]; access barriers got in 
their way. So our second response to 
Clarke’s challenge is that it will remain 
difﬁ  cult for researchers, particularly in 
resource-poor settings, to do systematic 
reviews unless the medical literature is 
made a freely available public resource. 
Many clinical trials, especially negative 
ones, remain unpublished, which 
prevents researchers from reviewing 
all the data on an important health 
issue. There are two main reasons why 
certain trials are not published: one is 
that the pharmaceutical industry has 
a long history of suppressing data that 
are commercially unfavorable and the 
second is that medical journals and 
the popular media favor publication 
of positive over negative trials (after 
all, negative trials do not make for a 
provocative newspaper headline). While 
we support the recent announcement 
on trial registration by the International 
Committee of Medical Journal 
Editors—as a condition of considering 
a trial for publication, member journals 
will require registration of the trial in 
a public trials registry [3]—we believe 
that this policy addresses only part of 
the problem.  
The scientiﬁ  c literature will remain 
biased unless the publishing industry 
changes its practices and provides 
a place where the results from all 
registered trials can be published. PLoS 
Medicine is committed to publishing 
high-quality negative trials. In this 
issue, for example, we publish an 
important randomized controlled trial 
of a malaria vaccine in 372 Gambian 
men, which found that the vaccine 
was ineffective at reducing the natural 
infection rate.
The internet makes it possible for 
every single clinical trial to be publicly 
and seamlessly tracked through three 
tiers. The ﬁ  rst tier is registration in a 
publicly available database. The second 
is the publication of a peer-reviewed 
summary of every trial, regardless of 
its outcome, in a traditional journal 
format, with annotations and critiques 
that help readers understand the 
trial’s implications. The third is the 
deposition of detailed trial data in a 
structured, computable format that 
allows sophisticated searching and 
analyses across trials. This format will 
allow the development of better tools to 
help clinicians apply trial results to their 
practice. For trial data to be as useful as 
possible, all three tiers must be publicly 
accessible. Assessment of each trial’s 
validity is critical, but should not stop 
crucial information about all trials being 
placed in the public domain. 
Trial registries exist, such as 
ClinicalTrials.gov and the International 
Standard Randomised Controlled Trial 
Number registry. Moreover, many trials 
are registered in a semi-public database 
maintained by the United States Food 
and Drug Administration, and there 
are compelling arguments (which 
Turner articulates in an essay published 
online ahead of our December issue 
[4]) for making this a truly public 
resource. Publicly accessible trial 
databases (such as the Trial Bank 
Project at http:⁄⁄rctbank.ucsf.edu) are 
under development. And as a publisher 
committed to open access, PLoS will 
provide the second, essential tier—
journals capable of peer reviewing and 
publishing an annotated report of every 
trial. Traditional medical journals, 
with their subscription-based model, 
are unlikely to be able to provide this 
service, because in order to attract 
subscribers they need to publish only 
the highest-proﬁ  le trials. We believe 
that an open-access model—in which 
the research funder pays a publication 
fee to recover the costs of peer review 
and for hosting the report on a secure 
server—is the best mechanism for 
creating such venues. We are working 
to make that happen.
Returning to Clarke’s challenge, 
our ﬁ  nal response is to say that we 
have a bold vision of a freely accessible 
online world of clinical trials—from 
registration to annotated summaries 
to trial databases. That world would 
be even richer if every systematic 
review were made freely available. We 
challenge the Cochrane Collaboration 
to put the full text of all of its reviews 
into the public domain. We hope the 
Cochrane Collaboration will join us in 
the open-access revolution.  
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